Table 2. . Type of second-line chemotherapy after first recurrence.
| Second-line chemotherapy | TTFields plus second-line chemotherapy (n = 144); n (%) | Second-line chemotherapy alone (n = 60); n (%) |
|---|---|---|
| Bevacizumab: | ||
| – Monotherapy | 61 (42) | 26 (43) |
| – Combination therapy | 18 (13) | 4 (7) |
| Lomustine, carmustine, fotemustine | 52 (36) | 23 (38) |
| Temozolomide | 25 (17) | 7 (12) |
| Irinotecan | 3 (2) | 2 (3) |
| Carboplatin | 3 (2) | 1 (2) |
| Procarbazine | 0 | 1 (2) |
TTFields: Tumor-treating fields.